Minghui Pharmaceutical to Present MHB088C Study for Recurrent/Metastatic Tumors at 2024 ASCO

Minghui Pharmaceutical, Inc., a company specializing in late-stage clinical biopharmaceuticals targeting autoimmune diseases and oncology, is set to showcase significant advancements at the upcoming ASCO Annual Meeting in Chicago. The event will feature Dr. Lin Shen of Beijing Cancer Hospital, who is scheduled to present findings from the Phase I/II clinical study of MHB088C, an innovative B7-H3-targeting antibody-drug conjugate (ADC) designed for patients with recurrent or metastatic solid tumors.

Dr. Shen's presentation is titled "Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors." This session, part of the Developmental Therapeutics focusing on Molecularly Targeted Agents and Tumor Biology, will take place on June 3, 2024, from 8:00 AM to 9:30 AM CDT. Dr. Shen’s oral presentation is slated for 8:00 AM and will last for six minutes.

MHB088C is a groundbreaking B7-H3 ADC developed through Minghui's SuperTopoiTM ADC platform. This new therapeutic agent boasts a proprietary payload, which is significantly more potent than existing treatments, specifically 5 to 10 times stronger than Dxd, without the associated risk of interstitial lung disease. Its distinctive feature is its superior binding and internalization efficacy, outperforming competitor antibodies. In preclinical trials, MHB088C demonstrated exceptional anti-tumor activity, proving 3 to 10 times more effective at eliminating tumor cells compared to competing compounds in xenograft models.

The safety profile of MHB088C has been promising, as evidenced by preclinical GLP tox studies which revealed no unique toxicities, especially no pulmonary toxicities. The highest identified non-severely toxic dose (HNSTD) was 30 mg/kg, administered bi-weekly for seven doses. The Phase I/II clinical study commenced with the first patient enrollment on June 20, 2023. Since then, over 150 patients with various tumor types have participated, receiving at least one dose of MHB088C. The results thus far indicate promising efficacy and a favorable safety profile. Minghui Pharmaceutical plans to initiate registrational trials for selected tumor types by the end of the year.

Minghui Pharmaceutical, Inc. stands out as a late-stage clinical biopharmaceutical company committed to addressing unmet medical needs in oncology and autoimmune diseases. The company leverages its deep expertise in medical science and its proprietary technology platforms to develop a robust pipeline of clinical-stage products. These include both first-in-class and best-in-class candidates, reflecting the company's innovation-driven approach.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!